Ground News

All Perspectives, One Place.

endpoints.news image

News from endpoints.news

Your destination for news from endpoints.news. See how endpoints.news’s media bias impacts the breaking news stories of today.

We’ve discovered 12 headlines written by endpoints.news during the past 3 months.

endpoints.news’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

endpoints.news’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about endpoints.news

Where is endpoints.news located?endpoints.news's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top endpoints.news News

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

58% Center coverage: 31 sources

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpointsDenifanstat demonstrated a favorable safety and tolerability profileDenifanstat was 98% and 178% more…See the Story

FDA Commissioner Pledges to Investigate Mifepristone

Mifepristone · United States

FDA Commissioner Pledges to Investigate Mifepristone

50% Right coverage: 24 sources

Food and Drug Administration Commissioner Marty Makary committed to reviewing the abortion drug mifepristone in a letter sent to Senator Josh Hawley (R-Mo.). See the Story

23andMe to Reopen Bankruptcy Court Auction After Anne Wojcicki Group's ...

23andMe to Reopen Bankruptcy Court Auction After Anne Wojcicki Group's ...

69% Left coverage: 13 sources

The saga surrounding the once-hot DNA testing company 23andMe has taken another unexpected turn. Last month, biotech firm Regeneron purchased the company’s assets—including its genetic database of around 15 million users—for $256 million at a bankruptcy auction, seemingly closing the deal. However, a larger bid from Anne Wojcicki, 23andMe’s co-founder and former CEO, has prompted a second auction. At a court hearing in St. Louis, Mo. yesterday (…See the Story

Blindspots

23andMe to Reopen Bankruptcy Court Auction After Anne Wojcicki Group's ...

0 of 19 Sources Lean Right

No coverage from Right Sources

23andMe to Reopen Bankruptcy Court Auction After Anne Wojcicki Group's ...

100% of Sources are High Factuality

Omada Health prices IPO at $19 per share, in middle of expected range

75% Center coverage: 8 sources

Omada Health priced its IPO at $19 per share on Thursday, in the middle of the expected range.Business · United States See the Story

Clinical Psychologist Explains How ADHD Drugs Work, Addresses Unscientific Harm Concerns

50% Left coverage: 8 sources

A recent report from Health Secretary Kennedy’s “Make America Healthy Again” commission argues children are being overmedicated for Attention-Deficit Hyperactivity Disorder. A UW-Madison clinical psychologist argues Kennedy’s statements on the harms of medications like Adderall aren’t based in science. The post Clinical psychologist explains how ADHD drugs work, addresses unscientific harm concerns appeared first on WPR.Robert F. Kennedy Jr. · United States See the Story

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

Among five tech sectors, China has the most immediate opportunity to overtake the US in biotechnology. That’s according to a report released on Thursday by the Harvard Belfer Center for Science and International Affairs that examined the geopolitics of technology across AI, biotech, semiconductors, space and quantum technology.Harvard · China Read Article

RFK Jr Looks to Alter Rare Disease Regulation by Fast-Tracking Drug Approvals - Pharmaceutical Technology

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.United States · United States See the Story

CMS talks health tech

On Tuesday, the Centers for Medicare and Medicaid Services convened a bunch of health tech leaders for a listening session on its recent request for information about improving health IT in the US.United States · United States Read Article

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal. In July 2015, Teva announced it would buy Allergan's generics business ...Innovation · New York Read Article

FDA's Prasad explains rationale behind pausing Valneva's chikungunya vaccine in seniors

The FDA and CDC's decision last month to pause administering Valneva's live-attenuated chikungunya vaccine in patients 60 and older was meant to provide more time to examine a potential causal relationship between the vaccine and ...FDA · United States Read Article

Cullinan's deal for T cell engager from China; Kardigan buys late-stage heart drug

Plus, news about Novartis, Signify Bio, Ocugen, Dynavax and ViGeneron: Cullinan Therapeutics gets rights to T cell engager developed in China: The company made a deal with Chongqing-based Genrix Bio for ...Chongqing · Chongqing Read Article

Breaking News Topics Related to endpoints.news